Intelligence Feed event · Macro · 2026-10-01

    Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial

    Question

    Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial

    Direct answer

    Boehringer Ingelheim and co-developer Zealand Pharma announced topline Phase III data from the SYNCHRONIZE-2 trial assessing survodutide in patients with obesity and type 2 diabetes. Treatment resulted in mean body weight reduction of up to 13.1% compared to 3.1% for placebo over 76 weeks. The drug achieved statistically significant improvements in blood sugar control, confirming clinical efficacy in complex patient populations and positioning the asset for regulatory submission filings.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-achieves-13-1-weight-loss-in-phase-iii-obesity-t2d-trial-8f94dc

    MACRO
    Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial
    Boehringer Ingelheim and co-developer Zealand Pharma announced topline Phase III data from the SYNCHRONIZE-2 trial assessing survodutide in patients with obesity and type 2 diabetes. Treatment resulted in mean body weight reduction of up to 13.1% compared to 3.1% for placebo over 76 weeks. The drug achieved statistically significant improvements in blood sugar control, confirming clinical efficacy in complex patient populations and positioning the asset for regulatory submission filings.
    ZLDPY
    Impact
    78
    OCT 1
    SIG
    90%
    ZLDPY
    Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D Trial
    Boehringer Ingelheim and co-developer Zealand Pharma announced topline Phase III data from the SYNCHRONIZE-2 trial assessing survodutide in patients with obesity and type 2 diabetes. Treatment resulted in mean body weight reduction of up to 13.1% compared to 3.1% for placebo over 76 weeks. The drug achieved statistically significant improvements in blood sugar control, confirming clinical efficacy in complex patient populations and positioning the asset for regulatory submission filings.
    → Positive Phase III efficacy data for survodutide advances late-stage commercialization milestones and royalty valuation for ZLDPY in the metabolic therapeutics market.
    Impact
    Boehringer Ingelheim and co-developer Zealand Pharma announced topline Phase III data from the SYNCHRONIZE-2 trial assessing survodutide in patients with obesity and type 2 diabetes. Treatment resulted in mean body weight reduction of up to 13.1% compared to 3.1% for placebo over 76 weeks. The drug achieved statistically significant improvements in blood sugar control, confirming clinical efficacy in complex patient populations and positioning the asset for regulatory submission filings.
    Affected
    ZLDPY
    Transmission
    Positive Phase III efficacy data for survodutide advances late-stage commercialization milestones and royalty valuation for ZLDPY in the metabolic therapeutics market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYroyalty stream and milestone revenue expansion from Phase III clinical successUp1-5dZealand Pharma partner Boehringer Ingelheim announced positive SYNCHRONIZE-2 13.1% weight loss results.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month